Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Swain

Showing results (451-460 of 532) with videos related to

Pageof 54
Sort By:
Cancers|June 10, 2022
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast CancerChau Dang, Michael S Ewer, Suzette Delaloge, et al.
JCO Precision Oncology|January 31, 2025
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast CancersArielle L Heeke, Andrew Elliott, Kaitlyn O'Keefe, et al.
Clinical Breast Cancer|June 21, 2011
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research GroupPriya Rastogi, Marc E Buyse, Sandra M Swain, et al.
Vaccine|March 15, 2006
De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responsesDanher Wang, Alan L Schmaljohn, Nicholas U Raja, et al.
Anti-Cancer Drugs|August 24, 2013
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxelJavier Cortés, Sandra M Swain, Iveta Kudaba, et al.
Gastroenterology|January 10, 2012
Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivityJill M Hoffman, Karl Tyler, Sarah J MacEachern, et al.
Breast Cancer Research and Treatment|January 14, 2016
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and AxlJennifer L Dine, Ciara C O'Sullivan, Donna Voeller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31Elizabeth Tan-Chiu, Greg Yothers, Edward Romond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2010
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatmentS Dawood, S D Merajver, P Viens, et al.
NPJ Breast Cancer|September 26, 2017
Video intervention increases participation of black breast cancer patients in therapeutic trialsBrandi N Robinson, Antoinette F Newman, Eshetu Tefera, et al.
Pageof 54

Showing results (451-460 of 532) with videos related to

Sort By:
Pageof 54
Cancers|June 10, 2022
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast CancerChau Dang, Michael S Ewer, Suzette Delaloge, et al.
JCO Precision Oncology|January 31, 2025
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast CancersArielle L Heeke, Andrew Elliott, Kaitlyn O'Keefe, et al.
Clinical Breast Cancer|June 21, 2011
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research GroupPriya Rastogi, Marc E Buyse, Sandra M Swain, et al.
Vaccine|March 15, 2006
De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responsesDanher Wang, Alan L Schmaljohn, Nicholas U Raja, et al.
Anti-Cancer Drugs|August 24, 2013
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxelJavier Cortés, Sandra M Swain, Iveta Kudaba, et al.
Gastroenterology|January 10, 2012
Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivityJill M Hoffman, Karl Tyler, Sarah J MacEachern, et al.
Breast Cancer Research and Treatment|January 14, 2016
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and AxlJennifer L Dine, Ciara C O'Sullivan, Donna Voeller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31Elizabeth Tan-Chiu, Greg Yothers, Edward Romond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2010
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatmentS Dawood, S D Merajver, P Viens, et al.
NPJ Breast Cancer|September 26, 2017
Video intervention increases participation of black breast cancer patients in therapeutic trialsBrandi N Robinson, Antoinette F Newman, Eshetu Tefera, et al.
Pageof 54